Ritlecitinib is a pyrrolopyrimidine with a 7H-pyrrolo[2,3-d]pyrimidine core substituted at position 4 by a [(3R,6S)-6-methyl-1-(prop-2-enoyl)piperidin-3-yl]amino group. It is a dual inhibitor of Janus kinase 3 and the TEC family of tyrosine kinases. It functions as an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor, an antirheumatic, anti-inflammatory, immunosuppressive, and dermatologic drug. It is classified as a pyrrolopyrimidine, N-acylpiperidine, secondary amino compound, member of acrylamides, and tertiary carboxamide. It is the conjugate base of ritlecitinib(1+).
